Literature DB >> 17269886

Ocular and systemic manifestations after oral administration of a high dose of enrofloxacin in cats.

Marnie M Ford1, Richard R Dubielzig, Elizabeth A Giuliano, Cecil P Moore, Kristina L Narfström.   

Abstract

OBJECTIVE: To characterize the effects of oral administration of a high dose of enrofloxacin to cats. ANIMALS: 24 (12 male and 12 female) young healthy cats. PROCEDURES: Cats were allocated on the basis of sex into 2 groups (4 males and 4 females/ group) from which 3 subgroups for 3 durations (3, 5, or 7 days) of enrofloxacin (50 mg/kg, PO, q 24 h) or control solution (1 mL of water, PO, q 24 h) administration that began on day -1 were created. Funduscopic examinations were performed daily. Electroretinography (ERG) was performed before and every 2 to 3 days after the start of oral administration. Four cats/study group were euthanized on days 3, 5, and 7, and eyes were collected for light and electron microscopic evaluations.
RESULTS: Neurologic, funduscopic, and ERG abnormalities were evident only in cats administered enrofloxacin. Funduscopic changes (granular appearance or graying of the area centralis) were noticed on or before day 3 (after only 3 days of enrofloxacin administration), with subsequent similar changes along the visual streak. Vascular attenuation (between days 2 and 4) and generalized tapetal hyperreflectivity (between days 5 and 7) followed. Reduction in b-wave ERG amplitude preceded funduscopic changes. Morphologic changes in the photoreceptor layers correlated with duration of enrofloxacin administration, with generalized degenerative changes evident after 3 doses. CONCLUSIONS AND CLINICAL RELEVANCE: The study indicated that a high dose of enrofloxacin (50 mg/kg/d, PO) induced retinal and systemic changes. Enrofloxacin at 10 times the recommended dosage is acutely toxic to the outer retina of clinically normal cats.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17269886     DOI: 10.2460/ajvr.68.2.190

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  8 in total

1.  Diagnostic ophthalmology. Retinal degeneration.

Authors:  Lynne S Sandmeyer; Bruce H Grahn
Journal:  Can Vet J       Date:  2008-11       Impact factor: 1.008

2.  The use of vascular access ports for blood collection in feline blood donors.

Authors:  Isabelle Aubert; Anthony C G Abrams-Ogg; Anne M Sylvestre; Doris H Dyson; Dana G Allen; Ian B Johnstone
Journal:  Can J Vet Res       Date:  2011-01       Impact factor: 1.310

Review 3.  Adverse effects of antimicrobials via predictable or idiosyncratic inhibition of host mitochondrial components.

Authors:  Alison E Barnhill; Matt T Brewer; Steve A Carlson
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

4.  Effect of Antibiotic Class on Stroke Outcome.

Authors:  Dannielle Zierath; Allison Kunze; Leia Fecteau; Kyra Becker
Journal:  Stroke       Date:  2015-07-02       Impact factor: 7.914

5.  Retinal safety of a new fluoroquinolone, pradofloxacin, in cats: assessment with electroretinography.

Authors:  Andre Messias; Florian Gekeler; Alfred Wegener; Klaus Dietz; Konrad Kohler; Eberhart Zrenner
Journal:  Doc Ophthalmol       Date:  2007-10-02       Impact factor: 2.379

6.  Granulomatous colitis: more than a canine disease? A case of Escherichia coli-associated granulomatous colitis in an adult cat.

Authors:  Rodolfo Oliveira Leal; Kenny Simpson; Mélanie Fine; Jean-Charles Husson; Juan Hernandez
Journal:  JFMS Open Rep       Date:  2017-09-19

7.  Ophthalmic findings in sheep treated with closantel in Curitiba, Brazil.

Authors:  Marianna Bacellar-Galdino; Fabiano Montiani-Ferreira; Andre Tavares Somma; Ricardo Guilherme D'Otaviano de Castro Vilani; Ivan Roque de Barros Filho
Journal:  Vet World       Date:  2020-05-08

Review 8.  Enrofloxacin-The Ruthless Killer of Eukaryotic Cells or the Last Hope in the Fight against Bacterial Infections?

Authors:  Łukasz Grabowski; Lidia Gaffke; Karolina Pierzynowska; Zuzanna Cyske; Marta Choszcz; Grzegorz Węgrzyn; Alicja Węgrzyn
Journal:  Int J Mol Sci       Date:  2022-03-26       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.